RU2013131241A - Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака - Google Patents

Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака Download PDF

Info

Publication number
RU2013131241A
RU2013131241A RU2013131241/15A RU2013131241A RU2013131241A RU 2013131241 A RU2013131241 A RU 2013131241A RU 2013131241/15 A RU2013131241/15 A RU 2013131241/15A RU 2013131241 A RU2013131241 A RU 2013131241A RU 2013131241 A RU2013131241 A RU 2013131241A
Authority
RU
Russia
Prior art keywords
cancer
formula
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
RU2013131241/15A
Other languages
English (en)
Russian (ru)
Inventor
Лоран Дебюсш
Карлос ГАРСИЯ-ЭСЧЕВЕРРИЯ
Цзяньго МА
Стюарт МАКМИЛЛАН
Дженет Энн Мойрер ОГДЕН
Луак Венсан
Original Assignee
Санофи
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45464841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2013131241(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Санофи, Мерк Патент Гмбх filed Critical Санофи
Publication of RU2013131241A publication Critical patent/RU2013131241A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2013131241/15A 2010-12-09 2011-12-08 Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака RU2013131241A (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US42146510P 2010-12-09 2010-12-09
US61/421,465 2010-12-09
US201161436258P 2011-01-26 2011-01-26
US61/436,258 2011-01-26
US201161467485P 2011-03-25 2011-03-25
US61/467,485 2011-03-25
FR1159940 2011-11-03
FR1159940 2011-11-03
PCT/US2011/063871 WO2012078832A1 (en) 2010-12-09 2011-12-08 Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer

Publications (1)

Publication Number Publication Date
RU2013131241A true RU2013131241A (ru) 2015-01-20

Family

ID=45464841

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013131241/15A RU2013131241A (ru) 2010-12-09 2011-12-08 Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака

Country Status (22)

Country Link
US (1) US20140024653A1 (ko)
EP (1) EP2648729A1 (ko)
JP (1) JP2013544892A (ko)
KR (1) KR20140011311A (ko)
CN (1) CN103402518A (ko)
AR (1) AR084216A1 (ko)
AU (1) AU2011338354A1 (ko)
BR (1) BR112013014198A2 (ko)
CA (1) CA2820748A1 (ko)
CL (1) CL2013001643A1 (ko)
CR (1) CR20130246A (ko)
DO (1) DOP2013000131A (ko)
MA (1) MA34815B1 (ko)
MX (1) MX2013006319A (ko)
NZ (1) NZ611581A (ko)
PE (1) PE20140702A1 (ko)
RU (1) RU2013131241A (ko)
SG (1) SG190368A1 (ko)
TW (1) TW201306837A (ko)
UY (1) UY33790A (ko)
WO (1) WO2012078832A1 (ko)
ZA (1) ZA201303687B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2869152A1 (en) * 2012-04-06 2013-10-10 Sanofi Methods for treating cancer using pi3k inhibitor and mek inhibitor
US20150297594A1 (en) * 2012-10-11 2015-10-22 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a MEK inhibitor
WO2015120289A1 (en) 2014-02-07 2015-08-13 Verastem, Inc. Methods and compositions for treating abnormal cell growth
WO2016014390A1 (en) * 2014-07-25 2016-01-28 Merck Patent Gmbh Compositions and methods for mek inhibitor combination therapy in the treatment of cancer
BR112020012388A2 (pt) * 2017-12-22 2020-11-24 Adienne S.A. método para a determinação in vitro da potência de um ligante anti-cd26
JP2022547358A (ja) 2019-09-13 2022-11-14 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法
EP4228759A1 (en) * 2020-10-16 2023-08-23 Memorial Sloan Kettering Cancer Center Induction of ferroptosis for cancer therapy
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Also Published As

Publication number Publication date
DOP2013000131A (es) 2013-11-15
WO2012078832A1 (en) 2012-06-14
UY33790A (es) 2012-07-31
MA34815B1 (fr) 2014-01-02
MX2013006319A (es) 2013-07-03
KR20140011311A (ko) 2014-01-28
AU2011338354A1 (en) 2013-06-27
TW201306837A (zh) 2013-02-16
NZ611581A (en) 2015-02-27
CN103402518A (zh) 2013-11-20
ZA201303687B (en) 2014-01-29
PE20140702A1 (es) 2014-06-26
US20140024653A1 (en) 2014-01-23
SG190368A1 (en) 2013-06-28
AR084216A1 (es) 2013-05-02
BR112013014198A2 (pt) 2016-09-13
CR20130246A (es) 2013-09-03
CA2820748A1 (en) 2012-06-14
JP2013544892A (ja) 2013-12-19
CL2013001643A1 (es) 2014-03-28
EP2648729A1 (en) 2013-10-16

Similar Documents

Publication Publication Date Title
RU2013131241A (ru) Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
RU2012118974A (ru) Комбинации ингибитора pi3k и ингибитора мек
TR201807411T4 (tr) DNA-PK inhibitörleri.
RU2014141362A (ru) Комбинированная терапия пролиферативных нарушений
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
RU2016102158A (ru) Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака
MX2012010226A (es) Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal.
RU2015106524A (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ ИНГИБИТОРА CDK4/6 И ИНГИБИТОРА В-Raf
RU2013147514A (ru) Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
MX2013010770A (es) Tratamiento de tumores solidos.
JP2013544892A5 (ko)
RU2018103064A (ru) Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли
WO2016133903A3 (en) Combination therapy for cancer treatment
RU2014144254A (ru) Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
ATE435663T1 (de) Krebstherapie mit einem nukleären rezeptorliganden und einem hdac-hemmer
UA124238U (uk) Спосіб лікування раку молочної залози
RU2013127655A (ru) Фармацевтическая комбинация паклитаксела и ингибитора cdk
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
JP2016528238A (ja) イソチオシアネート系化合物と抗癌薬の併用
RU2006123939A (ru) Лечение остеопороза, связанного с терапией ингибиторами ароматазы
RU2013148817A (ru) Комбинации соединений-ингибиторов акт и мек и способы их применения
RU2015105821A (ru) Способ адъювантного лечения рака
RU2014112320A (ru) Ингибитор pi3k, предназначенный для применения для лечения рака кости или для предупреждения метастатической диссеминации первичных раковых клеток в кость

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20160328